Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06181656 · ClinicalTrials.gov registry record
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
A clinical trial of Esophageal Cancer and Pneumococcal Vaccine, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT06181656 is a study of Esophageal Cancer and Pneumococcal Vaccine that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06181656, a study of Esophageal Cancer and Pneumococcal Vaccine, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn how radiation treatment may affect your responses to vaccines against pneumonia.
Conditions Studied
Interventions
- BIOLOGICAL Pneumonia vaccine
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2027-07-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06181656
The ClinicalTrials.gov registry entry for NCT06181656 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (84% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pneumonia vaccine is the first listed.
NCT06181656 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06181656 about?
NCT06181656 is a clinical study titled "Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation". To learn how radiation treatment may affect your responses to vaccines against pneumonia.
What is the current status of trial NCT06181656?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2024-02-05. Estimated completion is 2027-07-04.
What conditions does trial NCT06181656 study?
This clinical trial studies the following conditions: Esophageal Cancer, Pneumococcal Vaccine, Lymphopenia, Chemoradiation.
What interventions are being tested in trial NCT06181656?
The interventions under investigation include: Pneumonia vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06181656?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06181656 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Registry for Esophageal and Gastroesophageal Junction Cancer
RECRUITING
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Retrospective Review of Esophageal Cancer at MSKCC
RECRUITING
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.